# EDGAR Filing Document

**Accession Number:** 0001162194
**File Stem:** 0000950170-25-101439
**Filing Date:** 2025-8
**Character Count:** 6557
**Document Hash:** 45aa4245a1fe8c26e69ffc0f1c808ed9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-101439.hdr.sgml**: 20250801

**ACCESSION NUMBER**: 0000950170-25-101439

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250801

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20250801

**DATE AS OF CHANGE**: 20250801

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STANDARD BIOTOOLS INC.
- **CENTRAL INDEX KEY:** 0001162194
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 770513190
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34180
- **FILM NUMBER:** 251176476

**BUSINESS ADDRESS:**
- **STREET 1:** 2 TOWER PLACE
- **STREET 2:** SUITE 2000
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 6502666000

**MAIL ADDRESS:**
- **STREET 1:** 2 TOWER PLACE
- **STREET 2:** SUITE 2000
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLUIDIGM CORP
- **DATE OF NAME CHANGE:** 20011113

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**Date of Report (date of earliest event reported): July 29, 2025**

------

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| Delaware<br>(State or other jurisdiction of <br>incorporation) | 001-34180<br>(Commission File Number) | 77-0513190<br>(I.R.S. Employer Identification Number) |
| 2 Tower Place**,** Suite 2000<br>South San Francisco**,** California 94080 | 2 Tower Place**,** Suite 2000<br>South San Francisco**,** California 94080 | 2 Tower Place**,** Suite 2000<br>South San Francisco**,** California 94080 |
| (Address of principal executive offices and zip code) | (Address of principal executive offices and zip code) | (Address of principal executive offices and zip code) |
| **(**650**)** 266-6000 | **(**650**)** 266-6000 | **(**650**)** 266-6000 |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common stock, $0.001 par value per share | LAB | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 29, 2025, the Board of Directors (the "Board") of Standard BioTools Inc. (the "Company") approved restricted stock unit ("RSU") retention awards for Michael Egholm, Ph.D., President & Chief Executive Officer of the Company, and Alex Kim, Chief Financial Officer of the Company, under the Company's Amended and Restated 2011 Equity Incentive Plan, as amended (the "2011 Plan"), effective as of August 1, 2025, consisting of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Subject to Dr. Egholm remaining actively employed with the Company through the applicable vesting dates, Dr. Egholm shall receive 3,000,000 RSUs, with 25% of the shares underlying the RSUs vesting on August 1, 2026, and the remaining 75% of the shares underlying the RSUs vesting in three equal annual installments thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Subject to Mr. Kim remaining actively employed with the Company through the applicable vesting dates, Mr. Kim shall receive 1,500,000 RSUs, with 40% of the shares underlying the RSUs vesting on July 20, 2026, and the remaining 60% of the shares underlying the RSUs vesting on July 20, 2027.

The RSU retention awards are subject to the terms and conditions of the 2011 Plan and the applicable RSU award agreements thereunder. The RSU retention awards are also subject to the provisions of the Company's 2023 Change of Control and Severance Plan and 2024 Change of Control and Severance Plan, as applicable, under which Dr. Egholm and Mr. Kim participate, respectively, and their respective Participation Agreements thereunder.

Additionally, on August 1, 2025, the Human Capital Committee of the Board approved an increase to the target amount of the annual performance bonus for Mr. Kim to 80% of Mr. Kim's base salary, effective as of January 1, 2025.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | August 1, 2025 | **STANDARD BIOTOOLS INC.** | **STANDARD BIOTOOLS INC.** |
|  |  | By: | /s/ Alex Kim |
|  |  | Name: | Alex Kim |
|  |  | Title: | Chief Financial Officer |

---

------